Gastroentérologie et hépatologie : ce qui a changé en 2022 [Gastroenterology and hepatology: what's new in 2022]
Fiche du document
1 février 2023
- doi: 10.53738/REVMED.2023.19.812.217
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2023.19.812.217
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36723651
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_43ED67B9D44E0
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2024-08-01 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
ColoscopyCiter ce document
M. Fraga et al., « Gastroentérologie et hépatologie : ce qui a changé en 2022 [Gastroenterology and hepatology: what's new in 2022] », Serveur académique Lausannois, ID : 10.53738/REVMED.2023.19.812.217
Métriques
Partage / Export
Résumé
The field of gastroenterology and hepatology is evolving constantly. In 2022, numerous landmark studies have been published in all its subspecialities including hepatology, functional diseases, interventional endoscopy, and inflammatory bowel disease. Among the most significant advances are the antiviral treatment for hepatitis D, the new Chicago classification version 4 for esophageal motility disorders, the first biological treatment for eosinophilic esophagitis, a randomized controlled trial about the efficacy of screening colonoscopy, novel endoscopic techniques such as G-POEM or endoscopic sleeve gastrectomy, and emerging IBD therapies such as ozanimod, upadacitinib or anti-IL23 antibodies.